![[PDF]](/pb-assets/Icons/adobe-pdf-icon-1498649896243.png){kind=icon}
Abstract
Background:
Neuroleptics are commonly used in palliative care settings. However, adverse events of neuroleptics, known as extrapyramidal symptoms (EPSs), might be overlooked in clinical practice. We conducted this study to explore the prevalence of EPSs in palliative care setting.
Methods:
This multicenter, prospective, observational study included patients who 1) were referred to either a specialist palliative care team or a palliative care unit, 2) had a diagnosis of cancer, and 3) were ≥20 years of age. We investigated the prevalence of EPSs and medications used. The primary outcome was the overall Drug-Induced Extrapyramidal Symptom Scale (DIEPSS) score.
Results:
Between November 2015 and October 2016, 149 patients from 5 centers in Japan were enrolled. The median age was 67 years (range: 21–88 years) and the study population included 81 men (54.4%). The cancer types included lung (55 patients, 36.9%), upper gastrointestinal tract (5, 3.3%), hepatobiliary (19, 12.8%); breast (12, 8.1%); head and neck (10, 6.7%), gynecologic (10, 6.7%), genitourinary (10, 6.7%), and others (28, 18.8%). The median Karnofsky performance status was 60 (20–100). Most patients (86.6%) did not experience delirium. Thirty-nine (26.2%) patients received one or more EPS-inducing medications. EPSs occurred in 4 (2.7%) patients with a cutoff score of 5 points for 5 parkinsonism items in DIEPSS.
References
| 1. |
Teunissen, SCCM, Wesker, W, Kruitwagen, C, de Haes, HCJM, Voest, EE, de Graeff, A. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage. 2007;34(1):94–104. doi:10.1016/j.jpainsymman.2006.10.015 Google Scholar | Crossref | Medline | ISI |
| 2. |
Campion, EW, Kelley, AS, Morrison, RS. Palliative care for the seriously ill. N Engl J Med. 2015;373(8):747–755. doi:10.1056/NEJMra1404684 Google Scholar | Crossref | Medline |
| 3. |
Breitbart, W, Alici, Y. Agitation and delirium at the end of life: “we couldn’t manage him”. JAMA. 2008;300(24):2898–2910. E1. doi:10.1001/jama.2008.885 Google Scholar | Crossref | Medline | ISI |
| 4. |
Breitbart, W, Alici, Y. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol. 2012;30(11):1206–1214. doi:10.1200/JCO.2011.39.8784 Google Scholar | Crossref | Medline |
| 5. |
National Comprehensive Cancer Network (NCCN) (2020). Antiemesis version 2.2020. Accessed September 11, 2020. https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf Google Scholar |
| 6. |
Hosker, CMG, Bennett, MI. Delirium and agitation at the end of life. BMJ. 2016;353:1–6. doi:10.1136/bmj.i3085 Google Scholar |
| 7. |
National Comprehensive Cancer Network (NCCN) (2020). Palliative Care version 1.2020. Accessed September 11, 2020. https://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf Google Scholar |
| 8. |
López-Sendón, JL, Mena, MA, de Yébenes, JG. Drug-induced parkinsonism in the elderly: incidence, management and prevention. Drugs Aging. 2012;29(2):105–118. doi:10.2165/11598540-000000000-00000 Google Scholar | Crossref | Medline |
| 9. |
Dayalu, P, Chou, KL. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother. 2008;9(9):1451–1462. doi:10.1517/14656566.9.9.1451 Google Scholar | Crossref | Medline |
| 10. |
Trosch, RM . Neuroleptic-induced movement disorders: deconstructing extrapyramidal symptoms. J Am Geriatr Soc. 2004;52(12 suppl):S266–S271. doi:10.1111/j.1532-5415.2004.52603.x Google Scholar | Crossref | Medline |
| 11. |
Stephen, P, Williamson, J. Drug-induced parkinsonism in the elderly. Lancet. 1984;324(8411):1082–1083. Accessed January 23, 2014. http://www.sciencedirect.com/science/article/pii/S0140673684915162 Google Scholar |
| 12. |
Ministry of Health L and W . Manual for managing severe side effects: drug-induced parkinsonism. Published 2006. Accessed September 11, 2020. http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1c01.pdf Google Scholar |
| 13. |
Inada, T . Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to Its Usage. Seiwa Shoten Publishers; 1996. Google Scholar |
| 14. |
Kim, J-H, Jung, HY, Kang, UG, et al. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders. Mov Disord. 2002;17(6):1354–1359. doi:10.1002/mds.10255 Google Scholar | Crossref | Medline |
| 15. |
Inada, T . DIEPSS Training DVD: Commentary Using Computer Graphics (NCDEU 2013 Japanese Version). Scales TJS of PR, ed. The Japanese Society of Psychiatric Rating Scales; 2013. Google Scholar |
| 16. |
Lingjaerde, O, Ahlfors, UG, Bech, P, Dencker, SJ, Elgen, K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100. Google Scholar |
| 17. |
Day, JC, Wood, G, Dewey, M, Bentall, RP. A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. Br J Psychiatry. 1995;166(5):650–653. doi:10.1192/bjp.166.5.650 Google Scholar | Crossref | Medline |
| 18. |
Fleishman, SB, Lavin, MR, Sattler, M, Szarka, H. Antiemetic-induced akathisia in cancer patients receiving chemotherapy. Am J Psychiatry. 1994;151(5):763–765. doi:10.1176/ajp.151.5.763 Google Scholar | Crossref | Medline |
| 19. |
Kawanishi, C, Onishi, H, Kato, D, et al. Unexpectedly high prevalence of akathisia in cancer patients. Palliat Support Care. 2007;5(4):351–354. Google Scholar |
| 20. |
Rashid, A, Baile, W, Olubajo, T, De La Garza, R. Incidence of antiemetic-induced akathisia in patients at a comprehensive cancer center. Psychooncology. 2018;27(4):1338–1340. doi:10.1002/pon.4597 Google Scholar | Crossref | Medline |
| 21. |
Forcen, FE, Matsoukas, K, Alici, Y. Antipsychotic-induced akathisia in delirium: a systematic review. Palliat Support Care. 2016;14(1):77–84. doi:10.1017/S1478951515000784 Google Scholar | Crossref | Medline |
| 22. |
Hisanaga, T, Shinjo, T, Imai, K, et al. Clinical guidelines for management of gastrointestinal symptoms in cancer patients: The Japanese Society of Palliative Medicine recommendations. J Palliat Med. 2019;22(8):986–997. doi:10.1089/jpm.2018.0595 Google Scholar | Crossref | Medline |
| 23. |
Kaneishi, K, Nishimura, K, Sakurai, N, et al. Use of olanzapine for the relief of nausea and vomiting in patients with advanced cancer: a multicenter survey in Japan. Support Care Cancer. 2016;24(6):2393–2395. doi:10.1007/s00520-016-3101-x Google Scholar | Crossref | Medline |
